Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: MONOGRAPH

Fluoxetine

Plain-language summaryIntrigue 70 / 100

Fluoxetine is the original Prozac, the drug that made SSRIs household vocabulary in the 1990s. It works by blocking the pump that pulls serotonin back into the nerve cell that released it, leaving more of the signal sitting in the gap between brain cells. Eli Lilly synthesized it in 1972; the FDA approved it in 1987. It is unusually long-lived in the body (the active leftover sticks around for over a week), which makes it forgiving of missed doses but also slow to clear if a doctor needs to switch medications. It also blocks the liver enzyme CYP2D6, which matters for drug interactions. Decades of trials in depression, OCD, bulimia, and anxiety have made it one of the most studied psychiatric drugs ever. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

Mature SSRI reference compound with exceptional evidence but near-zero novelty as a research target

Look, fluoxetine is one of the most consequential molecules in twentieth-century psychiatry. That’s exactly the problem. When a compound gets synthesized in 1972, approved in 1987, and prescribed to tens of millions of people before most of us owned a cell phone, there’s not a lot of frontier left to explore. The research literature on fluoxetine is not just mature, it’s geological. We’re not suggesting investigators ignore it. We are saying that putting it in a research library as a discovery target doesn’t make sense.

The mechanism story has some nuance worth acknowledging. Yes, fluoxetine is primarily a SERT inhibitor with a Ki around 1 nM, but the secondary 5-HT2C antagonism is pharmacologically real and does something that plain SERT blockade can’t fully explain. The disinhibition of noradrenergic and dopaminergic tone in the prefrontal cortex via that 5-HT2C route is the leading explanation for fluoxetine’s activating profile relative to other SSRIs. Thats not trivial. But its also not new. This was worked out in the 1990s and 2000s and the conversation has largely moved on to triple-reuptake inhibitors and psychoplastogens where the mechanism complexity is actually an open question.

Where fluoxetine earns its place is on the bench as a tool. It is the reference SSRI. If you’re validating a SERT binding assay, setting up an animal model of depression, or doing receptor selectivity work across the serotonergic system, fluoxetine is the positive control you reach for. The extraordinarily long half-life of the active norfluoxetine metabolite (seven to fifteen days) makes steady-state kinetics unusually predictable, which has genuine experimental utility. The CYP2D6 inhibition profile is also useful as a pharmacokinetic probe. These are real bench applications, just not frontier science.

The differentiation picture is honestly where fluoxetine falls hardest. Within the SSRI class, escitalopram and sertraline have largely displaced it clinically on tolerability grounds. The long half-life that makes PK work easier is also what makes titration and drug interactions more complicated. It’s not strictly worse than everything, it has real unique features, but calling it best-in-class on any dimension requires picking a dimension most clinicians and researchers have stopped caring about.

We think fluoxetine belongs in the library as a reference standard entry. It’s not a discovery target. It’s not interesting as a frontier compound. The score reflects a genuinely important, deeply understood molecule that a serious bench scientist would reach for as a control, not as a subject of primary investigation.

Novelty

10

Mechanism promise

22

In-category differentiation

28

Evidence quality

88

Translational signal

80

Research bench value

65

Rationale Fluoxetine scores high on evidence and translational signal because it is a fully approved antidepressant with decades of phase 3 data, but novelty is floor-level and the SERT-inhibition mechanism sits in the most saturated receptor class in psychopharmacology. Its research value today is almost entirely as a reference probe and positive control, not as a frontier investigation target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective serotonin reuptake inhibitor

The first widely prescribed SSRI; a long-acting serotonergic antidepressant and a foundational reference compound for serotonin pharmacology.

Abstract

Fluoxetine ((R/S)-N-methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; CAS 54910-89-3; molecular formula C17H18F3NO; molecular weight 309.33) is a phenoxyphenylpropylamine SSRI synthesized at Eli Lilly in 1972 and approved by the FDA in 1987 as the first commercial SSRI under the trade name Prozac. The compound exhibits high affinity for the serotonin transporter (SERT, Ki approximately 1 nM) with comparatively weak activity at the norepinephrine transporter (Ki approximately 240 nM) and the dopamine transporter. Notable for an extraordinarily long elimination half-life (1 to 3 days for the parent compound, 7 to 15 days for the active norfluoxetine metabolite) which renders steady-state achievement slow but mitigates discontinuation syndrome. Pharmacologically distinguished from later SSRIs by 5-HT2C antagonism that contributes to noradrenergic and dopaminergic disinhibition in the prefrontal cortex, partially explaining the activating subjective profile. Hepatic metabolism is via CYP2D6 (primary) and CYP3A4 (secondary); the compound is itself a potent CYP2D6 inhibitor, producing clinically significant interactions with TCAs, antipsychotics, and beta-blockers. Used widely as a reference SSRI in serotonergic mechanism studies, animal models of depression, and as a positive control in receptor binding and reuptake assays.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-201Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Clozapine

Plain-language summaryIntrigue 78 / 100

Clozapine (Clozaril) is the most effective antipsychotic ever developed, and it has held that title since the 1980s without serious challenger. It was approved by the FDA in 1989 specifically for treatment-resistant schizophrenia and remains the only drug demonstrated to reduce suicidality in schizophrenia. The catch is severe: roughly one in 100 patients develops agranulocytosis, a potentially fatal collapse of white blood cell production, which is why every patient on clozapine in the United States must submit to weekly, then biweekly, then monthly blood draws indefinitely. Mechanistically it is the prototype atypical antipsychotic, with weak D2 blockade compensated by potent 5-HT2A blockade and a wide net of effects on histamine, muscarinic, and adrenergic receptors. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

57/100

Gold standard for treatment-resistant schizophrenia but low novelty and exhausted mechanism space limit research appeal

Look, clozapine is one of the most clinically important psychiatric compounds in modern medicine. The gold standard for treatment-resistant schizophrenia since the early 1990s, it consistently outperforms every other antipsychotic in TRS populations across decades of multi-center trials. That 1% agranulocytosis incidence is genuinely dangerous and the weekly CBC monitoring requirement through the first six months is a real burden on both patient and system, and still no other drug in the class has managed to displace it for TRS. That clinical track record is not marketing. Its real, its replicated, and its durable.

The receptor pharmacology is what put clozapine on the map as a research object. The weak D2 antagonism (Ki ~130 nM) paired with potent 5-HT2A antagonism (Ki ~16 nM), plus a broad off-target profile spanning D4, muscarinic M1-M5, H1, alpha-1, and multiple 5-HT subtypes, gave investigators the receptor-binding template that defined the entire atypical antipsychotic class. The M1 affinity (Ki ~7 nM) is particularly interesting for anyone studying muscarinic contributions to cognition or psychosis. The M4 partial agonism that produces paradoxical hypersalivation in an otherwise anticholinergic compound is one of the genuinely under-worked threads still worth pursuing.

Here’s the thing though: as a forward-looking research target, novelty is a real problem. This is a 1989 approved drug whose core mechanism has been studied exhaustively for 35 years. The atypical class it spawned has been dissected from every angle conceivable. The literature isnt sparse, its saturated. You can open any receptor pharmacology textbook and find clozapine used as the canonical example. Investigators reach for it precisely because the answers are known, not because theres something new to find. Thats the opposite of an underexplored compound.

What keeps clozapine relevant in a research library is its probe and comparator value. For anyone working on antipsychotic mechanism studies, its the reference everyone is implicitly measuring against. For investigators studying TRS biology, its essentially the only validated positive control. For labs interrogating D4 receptor function specifically, clozapines selectivity profile is still a useful tool despite the years. We think the M4 partial agonism angle and the CYP1A2 metabolism interactions (particularly in smokers, who dramatically accelerate clearance) remain underexplored relative to the compounds clinical importance.

Honestly, the positioning is this: outstanding evidence quality, strong translational signal, real bench probe value in the right context, but genuinely low novelty and a mechanism space that most investigators have already mapped thoroughly. For a lab focused on whats next in CNS pharmacology, clozapine is background knowledge. For a lab working specifically on treatment resistance mechanisms, comparative antipsychotic pharmacology, or muscarinic-dopamine crosstalk, it earns its place on the bench.

Novelty

20

Mechanism promise

40

In-category differentiation

65

Evidence quality

82

Translational signal

78

Research bench value

75

Rationale Clozapine earns strong marks on evidence quality, translational signal, and bench probe value given its canonical reference-compound role and unmatched TRS clinical record, but 1989 FDA approval, fully characterized multireceptor pharmacology, and a thoroughly saturated literature drag novelty and mechanism scores down sharply. No scheduling cap or structural category cap applies; the score reflects a genuinely important but mature compound with limited frontier value for forward-looking research programs.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Atypical antipsychotic / D4-D2 multireceptor antagonist

The prototype atypical antipsychotic; the gold standard for treatment-resistant schizophrenia, limited by agranulocytosis risk requiring weekly blood monitoring.

Abstract

Clozapine (8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; CAS 5786-21-0; molecular formula C18H19ClN4; molecular weight 326.82) is a dibenzodiazepine atypical antipsychotic developed at Wander/Sandoz and approved by the FDA in 1989 under the trade name Clozaril. The compound is the prototype atypical antipsychotic, introducing the receptor profile that defines the class: weak D2 antagonism (Ki approximately 130 nM) combined with potent 5-HT2A antagonism (Ki approximately 16 nM), producing antipsychotic efficacy without the extrapyramidal symptoms typical of high-affinity D2 antagonists. Off-target activity is broad: H1, alpha-1, muscarinic M1-M5 (Ki approximately 7 nM at M1), 5-HT2C, 5-HT3, 5-HT6, 5-HT7 antagonism, contributing to sedation, weight gain, sialorrhea (paradoxical from M4 partial agonism), and orthostatic hypotension. The defining clinical feature is efficacy in treatment-resistant schizophrenia, where clozapine consistently outperforms other antipsychotics; the limitation is approximately 1 percent agranulocytosis incidence, requiring weekly CBC monitoring through the first 6 months and biweekly thereafter. Plasma half-life is 12 hours; metabolism is via CYP1A2 (primary), CYP3A4, CYP2D6. Used as the canonical atypical antipsychotic in mechanism studies and as the gold standard for treatment-resistant schizophrenia.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-232Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Buspirone

Plain-language summaryIntrigue 60 / 100

Buspirone (BuSpar) is the first non-benzodiazepine anxiolytic, approved by the FDA in 1986. Mechanistically it is unrelated to any sedative class: it is a partial agonist at the serotonin 5-HT1A receptor, with no GABA-A activity. That means it does not produce sedation, dependence, or withdrawal, and it has no recreational potential. The trade-off is that it works slowly (effects build over 2 to 4 weeks) and does not produce the fast acute relief patients expect from a benzodiazepine, which has limited its uptake despite its safety advantages. It is FDA-approved for generalized anxiety disorder and is widely used as add-on for SSRI-treated depression where some additional anxiolysis is needed. The active metabolite 1-PP is an alpha-2 antagonist contributing to the noradrenergic tone. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

Canonical 5-HT1A probe, mature anxiolytic with real evidence but thin novelty in 2026

Look, buspirone is a compound that was genuinely interesting in 1986. The first non-benzodiazepine anxiolytic approved by the FDA, it demonstrated that you could hit generalized anxiety disorder through 5-HT1A partial agonism rather than GABA-A potentiation, and that doing so meant no sedation, no tolerance, no physical dependence. For its era, that was a meaningful pharmacological statement. The mechanism story around autoreceptor desensitization, where the delayed anxiolytic onset (two to four weeks) reflects slow downregulation of presynaptic 5-HT1A somatodendritic autoreceptors, remains instructive for anyone studying serotonin system kinetics. The 1-PP metabolite’s alpha-2 antagonism adds a noradrenergic wrinkle that still gets cited in systems-level work.

The problem is that we’re rating research merit in 2026, not 1986. The 5-HT1A partial agonist mechanism is thoroughly mapped. There are no hidden pockets in this pharmacology waiting to be discovered by a bench investigator picking up buspirone today. Its Ki of approximately 21 nM and intrinsic activity around 35 percent are numbers that have appeared in textbooks for decades. Secondary D2 antagonism at roughly 100 nM is real but the clinical significance remains unclear after forty years of trying to pin it down. Thats not the profile of a compound that’s going to generate an interesting paper in 2026 unless you’re specifically using it as a reference probe.

And that’s honestly where buspirone still earns its keep. As the canonical 5-HT1A partial agonist, it is the go-to tool compound when you need to isolate this receptor’s contribution to a behavioral or neurochemical readout. Comparing full agonists, partial agonists, and antagonists at 5-HT1A? You’re reaching for buspirone. Disentangling 5-HT1A from 5-HT1B or 5-HT2A contributions in a circuit-level experiment? Buspirone is in the protocol. That probe value is real, particularly in translational anxiety models or serotonin-system interaction studies. It’s not a replacement for newer tools, but it’s not obsolete either.

What we don’t find compelling is the idea of prioritizing buspirone as a primary research target. Its evidence base is among the strongest in this library, multiple phase 3 RCTs, decades of replicated mechanism work, FDA approval since Reagan’s second term. But that evidence bulk is exactly the problem: the question has been answered. GAD pharmacology has moved on to SSRIs, SNRIs, and increasingly ketamine and psychoplastogen-adjacent compounds as the interesting frontier. Buspirone sits comfortably in the literature as a mature reference standard with modest differentiation from newer anxiolytics on actual clinical metrics. Score it accordingly.

Novelty

22

Mechanism promise

30

In-category differentiation

35

Evidence quality

72

Translational signal

65

Research bench value

60

Rationale Buspirone earns its score almost entirely from evidence quality, translational signal, and residual bench utility as the reference 5-HT1A partial agonist; novelty and mechanism promise are dragged down by 40 years of literature and a single-receptor story that the field has well characterized. No scheduling or category cap applies, but the raw calculation lands squarely in established-mature territory.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

5-HT1A partial agonist anxiolytic

An azapirone 5-HT1A partial agonist; a non-benzodiazepine anxiolytic without dependence or sedation.

Abstract

Buspirone (8-[4-(4-pyrimidin-2-yl-1-piperazinyl)butyl]-8-azaspiro[4.5]decane-7,9-dione; CAS 36505-84-7; molecular formula C21H31N5O2; molecular weight 385.50) is an azapirone 5-HT1A partial agonist developed at Bristol-Myers Squibb and approved by the FDA in 1986 under the trade name BuSpar. The compound is the first clinically approved non-benzodiazepine anxiolytic, distinguished by mechanism (5-HT1A partial agonism rather than GABA-A potentiation), tolerance/dependence profile (none), and absence of sedation. 5-HT1A affinity is approximately 21 nM (intrinsic activity approximately 35 percent); secondary D2 antagonism (Ki approximately 100 nM) is of unclear clinical significance. The active metabolite 1-(2-pyrimidinyl)piperazine (1-PP) is an alpha-2 adrenergic antagonist contributing to noradrenergic effects. Onset of anxiolytic effect is delayed (2 to 4 weeks), reflecting the time course of 5-HT1A autoreceptor desensitization. Plasma half-life is 2 to 3 hours; metabolism is extensive via CYP3A4 with significant first-pass effect (oral bioavailability approximately 4 percent). Approved for generalized anxiety disorder. Used as the canonical 5-HT1A partial agonist in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-248Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Cardarine (GW-501516)

Our opinion on this compoundNiche research probe

43/100

Canonical PPAR-delta probe with real bench utility and a decisively dead translational path

Look, GW-501516 occupies a genuinely unusual position in the research compound landscape. It’s not a novel discovery and it’s not a failed hypothesis. It’s a tool with real utility that was abandoned for safety reasons, and understanding that distinction matters for how you think about it.

The mechanism is legitimate. PPAR-delta activation in skeletal muscle drives fatty acid oxidation and mitochondrial biogenesis through the PGC-1alpha axis. GSK’s phase 2 work in dyslipidemia showed real changes: HDL going up, triglycerides coming down. The biology is coherent and the compound does what it’s supposed to do. Thats actually part of what makes the carcinogenicity story so uncomfortable: this isn’t a failed mechanism, it’s a working mechanism in a compound that accelerates tumor growth at the same time.

The 2007 carcinogenicity data is what ended the GSK program. Long-term studies in both rats and mice showed dose-dependent tumor formation across multiple organ systems at every dose level tested. Not a marginal finding in one tissue at high dose: multiple tissues, multiple species, dose-response fully intact. WADA banned it in 2009. The recreational community largely ignored both of these facts, which is its own kind of signal about how people evaluate uncomfortable data when a compound does something they want it to do.

Here’s what keeps GW-501516 on the map for serious researchers: it remains the most well-characterized PPAR-delta agonist available for academic metabolic research. If you want to study PPAR-delta biology, fat oxidation pathways, mitochondrial biogenesis signaling, or the relationship between endurance capacity and substrate utilization, GW-501516 is still the reference compound. There arent many clean alternatives with comparable depth of characterization. That’s real bench value, and we give it credit for that specifically.

What it doesn’t have is a translational future. The clinical development program is dead and is not coming back. Any research program using this compound has to be oriented toward mechanistic probe work, not toward a clinical endpoint. That’s a legitimate scientific purpose, and there are genuine questions about PPAR-delta biology worth pursuing. But the constrained scope is real, and it shows up in the score.

We think the honest framing is: useful tool, dangerous compound, dead translational path. For a researcher working on PPAR-delta biology, muscle metabolism, or mitochondrial signaling in skeletal tissue, this compound is worth understanding. For anyone thinking about a translational arc or a human-facing program, there is nothing here to build toward. The score reflects that balance: a solid niche probe with no credible exit toward clinical relevance.

Novelty

30

Mechanism promise

38

In-category differentiation

58

Evidence quality

50

Translational signal

30

Research bench value

62

Rationale GW-501516 earns its differentiation and bench-value scores as the reference PPAR-delta agonist with genuine phase 2 lipid data, but tanks on translational signal and novelty because the clinical program is permanently closed by dose-dependent multi-organ carcinogenicity across both rodent species; no structural cap applies because the mechanism is intact and validated, only the safety profile is fatal.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

PPAR-delta agonist (not a SARM)

A PPAR-delta agonist developed for dyslipidemia; widely used recreationally as an endurance enhancer despite cancer findings in long-term rodent studies.

Abstract

Cardarine (GW-501516, Endurobol; CAS 317318-70-0; molecular formula C21H18F3NO3S2; molecular weight 453.50) is a peroxisome proliferator-activated receptor delta (PPAR-delta) agonist developed at GlaxoSmithKline for dyslipidemia. The compound is not a SARM; it is grouped with SARMs in popular discourse owing to similar recreational use patterns. PPAR-delta activation in skeletal muscle increases fatty acid oxidation, mitochondrial biogenesis, and endurance capacity. Phase 2 trials in dyslipidemia demonstrated favorable lipid profile changes (HDL increase, triglyceride decrease). Development was halted by GSK in 2007 after long-term carcinogenicity studies in rats and mice showed dose-dependent tumor formation in multiple organs at all dose levels tested. The compound retains research utility as the canonical PPAR-delta agonist for academic metabolic research and is widely used recreationally despite the carcinogenicity signal; banned by WADA. Plasma half-life is approximately 24 hours.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-265Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Dutasteride

Plain-language summaryIntrigue 60 / 100

Dutasteride (Avodart) is the more aggressive cousin of finasteride, approved in 2002. It blocks both type I and type II 5-alpha-reductase (finasteride mainly hits type II), suppressing plasma DHT by 90 to 95 percent rather than 65 to 70 percent. That makes it more effective for prostate enlargement and, in head-to-head trials, slightly better for hair loss, but it also produces a higher rate of sexual side effects. The very long half-life (about five weeks) means the effect persists long after stopping. The post-finasteride-syndrome concern applies here too. Often used off-label for hair loss in patients who do not respond to finasteride. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

51/100

Canonical dual 5AR inhibitor with mature mechanism, strong evidence base, and limited research novelty

Look, dutasteride is not a frontier compound. FDA approval 2002, mechanism completely characterized, clinical literature extensive. But ‘mature’ doesn’t mean ‘worthless as a research tool,’ and that’s the nuance worth preserving here.

The core pharmacology: dutasteride inhibits both 5-alpha-reductase isozymes, type I (Ki approximately 0.6 nM) and type II (Ki approximately 0.3 nM). Finasteride is primarily a type II inhibitor. The practical consequence is plasma DHT suppression of 90 to 95 percent versus 65 to 70 percent for finasteride at steady state. If your research question requires near-complete androgen withdrawal at the tissue level without castration, dutasteride is the cleanest tool available. No other 5AR inhibitor comes close on DHT floor, which matters when the difference between partial and near-complete suppression is exactly what you’re trying to study.

That differentiation point is real and it keeps the bench value score honest. For investigators studying DHT-mediated signaling in prostate, scalp follicle, or neural tissue, the choice between partial or near-complete 5AR inhibition is not trivial. The 5-week plasma half-life is both a feature and a design constraint: steady state takes time to achieve and washout takes longer, so crossover study designs require careful planning. Investigators who haven’t accounted for the slow offset have burned time and reagents on what were effectively underpowered comparisons.

The evidence base is genuinely strong. Multiple phase 3 RCTs for BPH, a growing off-label AGA literature where it consistently outperforms finasteride on hair count endpoints, and replicated mechanism across independent labs. This is not a single-consortium situation, and thats worth something in a space where a lot of peptide and nootropic compounds rely on a handful of groups.

What we don’t like here is the novelty picture. There’s nothing left to discover about the core mechanism. The interesting questions now are downstream: what are the tissue-specific consequences of near-complete DHT suppression that partial inhibition misses? Are there neurological effects from deeper androgen withdrawal that inform post-finasteride syndrome biology? That’s where the living research is happening, and dutasteride is a tool in that work, not the subject of it.

We think investigators working on androgen biology, AGA mechanisms, or prostate signaling should have dutasteride available as a reference probe. It does what it says, reliably, in real people. But if you’re looking for something novel to anchor a research program, this isn’t it. It’s a well-lit room, not an unexplored one.

Novelty

22

Mechanism promise

35

In-category differentiation

60

Evidence quality

76

Translational signal

73

Research bench value

57

Rationale Dutasteride scores well on evidence and translational signal (FDA-approved 2002, multiple phase 3 RCTs, unambiguous 90-95% DHT suppression in humans) but takes a significant hit on novelty and mechanism promise because the pharmacology is completely mapped after two decades of clinical use. Differentiation is elevated because nothing in the 5AR class matches its suppression depth, preserving its value as the canonical reference probe for androgen biology research.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Dual 5-alpha-reductase I/II inhibitor

A 4-azasteroid dual 5-alpha-reductase inhibitor (types I and II); more complete DHT suppression than finasteride.

Abstract

Dutasteride ((5-alpha,17-beta)-N-{2,5-bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide; CAS 164656-23-9; molecular formula C27H30F6N2O2; molecular weight 528.53) is a 4-azasteroid dual 5-alpha-reductase inhibitor developed at GlaxoSmithKline and approved by the FDA in 2002 under the trade name Avodart. Distinct from finasteride by inhibition of both 5AR isozymes (type I Ki approximately 0.6 nM, type II Ki approximately 0.3 nM, both substantially more potent than finasteride at type II). Plasma DHT is reduced by approximately 90 to 95 percent at the 0.5 mg dose, compared to 65 to 70 percent for finasteride. Plasma half-life is approximately 5 weeks (the longest in the 5AR inhibitor class), reflecting tight tissue binding. Approved for benign prostatic hyperplasia; off-label use in androgenetic alopecia (often more effective than finasteride). The longer half-life means slower offset of effect on discontinuation but also slower washout for fertility planning. Sexual side effects parallel finasteride. Used as the canonical dual 5AR inhibitor in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-280Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Dasatinib

Plain-language summaryIntrigue 80 / 100

Dasatinib (Sprycel) is a multi-target kinase inhibitor approved in 2006 for chronic myeloid leukemia and Philadelphia-chromosome-positive ALL. The longevity world cares about it for a different reason: in 2015, Kirkland and Tchkonia at Mayo Clinic showed that dasatinib combined with quercetin (a natural flavonoid) selectively kills senescent cells, those zombie cells that accumulate with age and pump out inflammatory signals. The combination, dubbed D+Q, became the prototype senolytic regimen and is in human trials for diabetic kidney disease, Alzheimer disease, and idiopathic pulmonary fibrosis. The intermittent dosing (a few days per month) is meant to clear senescent cells without sustained kinase inhibitor exposure. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

60/100

Canonical senolytic tool compound with real clinical pipeline but evidence still maturing

Look, dasatinib is a case where the original compound and the interesting research are almost two different things. As a BCR-ABL/Src kinase inhibitor for CML, it’s a well-understood oncology tool that’s been on the market since 2006. That part of the story is mature. What we’re interested in here is the senolytic application, which is effectively a different compound in terms of what investigators are actually doing with it.

The Kirkland and Tchkonia group at Mayo Clinic is the origin point for the D+Q framing. The 2015 paper in Aging Cell showed that dasatinib preferentially kills senescent fat cell progenitors while leaving healthy cells largely intact, and quercetin covers the epithelial senescent cell population that dasatinib misses. The mechanism isn’t just “it’s cytotoxic”; it’s targeting the pro-survival networks senescent cells depend on: ephrin receptors, BCR-ABL-related kinase activity in mesenchymal lineages, PI3K/AKT signaling. Selective enough to be useful, broad enough to clear the target population. Thats a real biological lever, and it makes the D+Q framing more than a convenience stack.

Clinical translation is moving. There’s a 2019 pilot in idiopathic pulmonary fibrosis (Kirkland, published in EBioMedicine) showing improved physical function measures in a small N. Trials in diabetic kidney disease have shown some early eGFR-related signals. The Alzheimer’s indication is under active investigation across multiple sites. What we dont have yet is a clean phase 3 confirmation; the trials are phase 1/2, mostly single-site, and effect sizes in the early data are modest. The IPF result looks real but hasn’t been replicated at scale.

Where dasatinib earns its keep in a research library is bench utility. If you’re running a senolytic program, this is your reference compound for the mesenchymal compartment. You can’t do credible senolytic biology without it as a comparator. The combination with quercetin is the canonical positive control in the field. That’s indispensable tool value even before you factor in the clinical translation story.

What we like: the mechanism is genuinely interesting, the clinical pipeline is real, and this compound occupies a position no other small molecule currently fills in aging biology. What we don’t like: the evidence base for the senolytic indication is still early, the oncology-derived dosing (even the intermittent 3-days-per-month approach) carries a meaningful adverse effect profile that complicates healthy-aging research design, and the human signal needs considerably more work before anyone should treat this as a resolved story. Compelling for investigators in the senolytic space; not yet a priority for those working adjacent to it.

Novelty

52

Mechanism promise

65

In-category differentiation

68

Evidence quality

52

Translational signal

55

Research bench value

72

Rationale Dasatinib scores primarily on differentiation and bench utility as the reference mesenchymal senolytic in the D+Q combination; novelty is tempered by its 2006 approval and now-decade-old senolytic repurposing, and the clinical evidence base remains phase 1/2 with modest effect sizes and limited replication.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tyrosine kinase inhibitor / senolytic

A multi-target tyrosine kinase inhibitor approved for chronic myeloid leukemia; repurposed in senolytic combination therapy with quercetin (D+Q).

Abstract

Dasatinib (BMS-354825; CAS 302962-49-8; molecular formula C22H26ClN7O2S; molecular weight 488.01) is a multi-target tyrosine kinase inhibitor developed at Bristol-Myers Squibb and approved by the FDA in 2006 under the trade name Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive ALL. The senolytic application emerged from work by Kirkland and Tchkonia at Mayo Clinic (2015 onward) demonstrating that the combination of dasatinib (targeting senescent cells of mesenchymal origin) and quercetin (targeting senescent cells of epithelial origin) selectively eliminates senescent cells while sparing healthy cells. The D+Q regimen has been advanced into multiple clinical trials in idiopathic pulmonary fibrosis, diabetic kidney disease, Alzheimer disease, and other age-related conditions, with intermittent dosing (e.g., 100 mg daily for 3 days monthly) hypothesized to clear accumulated senescent cells without continuous chemotherapy exposure. Plasma half-life is approximately 5 hours; metabolism is via CYP3A4. Used as the canonical senolytic small molecule with clinical translation.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-297Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Latrepirdine (Dimebon)

Our opinion on this compoundRetracted or disproven

30/100

High-profile phase 3 failure; residual probe value for multi-target receptor pharmacology only

Look, Latrepirdine is one of the most instructive failure stories in CNS pharmacology, and not in a way that makes it a compelling research target today. The 2008 Doody et al. phase 2 trial looked genuinely exciting: a small Russian cohort, significant ADAS-cog improvements, a multi-target receptor profile that nobody had properly characterized, and a mitochondrial protection story that felt like it could explain everything. Pfizer and Medivation saw it too, licensed it, and ran two large phase 3 trials. Both failed. CONNECTION and CONCERT were well-powered, well-designed trials and they found nothing. That’s not a marginal miss; thats a decisive refutation of the clinical hypothesis.

The mechanism story never really resolved. The proposed mitochondrial protective effects, seen in some Bhagya Bhardwaj and Bhatt lab preclinical work around 2009-2010, were speculative and never validated in humans. The receptor profile is genuinely broad: H1, alpha-1, alpha-2, 5-HT2A, 5-HT5A, 5-HT6, D1, D2. Interesting on paper. In practice, non-selective polypharmacology of this kind is hard to interrogate cleanly, and the carboline scaffold doesn’t give you the kind of selectivity you’d want for mechanistic studies. You can’t easily tease apart which receptor is doing what.

We think the only honest argument for latrepirdine as a research compound in 2025 is as a pharmacological probe for studying multi-receptor interaction effects in the receptor profile it occupies. Its beta-carboline scaffold is at least structurally distinct, and theres a small body of work using it to study 5-HT6 and 5-HT5A receptor contributions in mixed-target paradigms. For investigators specifically working on receptor polypharmacology or building multi-target binding models, it has some real but narrow utility. The compound is commercially available from several RUO vendors, synthesis is straightforward, and the pharmacokinetics are reasonably well characterized.

What we don’t like: the translational arrow points firmly backwards. The mitochondrial story is unvalidated and the primary indication collapsed publicly. The novelty is minimal, the differentiation from other available probes in its receptor class is low, and the evidence base that actually exists is evidence of failure. That phase 2 signal is almost certainly a statistical artifact or a trial design artifact; the Russian cohort, the small N, the endpoint choices. Investigators who want to study the receptor space latrepirdine occupies have better, cleaner probes available. This compound belongs in the case-study file, not on the active screening list.

Novelty

25

Mechanism promise

30

In-category differentiation

20

Evidence quality

55

Translational signal

15

Research bench value

40

Rationale Phase 3 CONNECTION and CONCERT trials decisively refuted the phase 2 signal in Alzheimer disease, collapsing the primary translational story; the compound retains narrow utility as a multi-target receptor probe by virtue of its carboline scaffold and unusual receptor breadth, but a serious investigator has no strong reason to prioritize it over better-validated tools.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Multi-target antihistamine / mitochondrial protectant

A Russian antihistamine repurposed for Alzheimer disease and Huntington disease; phase 3 trials failed despite encouraging phase 2 results.

Abstract

Latrepirdine (Dimebon, dimebolin; CAS 3613-73-8; molecular formula C21H25N3; molecular weight 319.45) is a tetrahydro-gamma-carboline antihistamine developed in the USSR in the 1960s and approved in Russia for allergic conditions. The compound is a non-selective receptor blocker (H1, alpha-1, alpha-2, 5-HT2A, 5-HT5A, 5-HT6, D1, D2). The Alzheimer disease application emerged from drug repurposing screens in the 2000s; preclinical studies suggested mitochondrial protective effects independent of the receptor binding. Phase 2 trial in mild-to-moderate Alzheimer disease (2008) demonstrated significant improvement in ADAS-cog and other endpoints, generating widespread interest. Phase 3 trials (CONNECTION, CONCERT) in 2010-2012 failed to replicate the phase 2 effects, marking one of the highest-profile late-stage failures in CNS drug development. The compound is no longer in clinical development. Used as a research compound for multi-target receptor pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-314Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
JZL184

Plain-language summaryIntrigue 50 / 100

JZL184 is the canonical research probe for blocking MAGL, the enzyme that breaks down the endocannabinoid 2-AG. It was developed in the Cravatt laboratory at Scripps and works by permanently inactivating the enzyme, which raises 2-AG levels and produces cannabinoid-like effects without direct receptor agonism. Animal work shows analgesic and anti-inflammatory activity, but a meaningful complication is that JZL184 also partially inhibits FAAH (about 300-fold MAGL preference), muddying interpretation of some early studies. Cleaner second-generation tools like KML29 have largely replaced it for definitive mechanism work. Not a clinical compound. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

55/100

The canonical covalent MAGL probe; indispensable for 2-AG signaling research but carries no clinical trajectory of its own

Look, JZL184 is one of those compounds where the story is almost entirely about what it lets you do at the bench rather than what it might eventually do in a person. Brian Cravatt’s group at Scripps published the original covalent piperidinyl-carbamate scaffold in 2009, and the compound has been the go-to MAGL inhibitor ever since. That’s roughly fifteen years of multi-lab use, which tells you something: the selectivity profile held up, the covalent mechanism turned out to be a feature rather than a liability for probe work, and nobody has made something clearly better for the specific task of irreversibly blocking MAGL while leaving FAAH intact.

The mechanism is genuinely elegant. JZL184 carbamoylates the active-site serine of MAGL, producing irreversible inactivation. The selectivity over FAAH runs about 300-fold, which is what lets investigators dissect the 2-AG arm of endocannabinoid signaling from the AEA arm without crossover noise. Thats critical: AEA and 2-AG occupy very different regulatory niches at CB1 synapses, and pharmacologically parsing them has been a long-standing methodological problem. JZL184 solved the MAGL side of that problem cleanly. The behavioral pharmacology that follows from MAGL inhibition is more THC-like than FAAH inhibition (anxiolysis, analgesia, hypothermia, catalepsy at higher doses), which reflects the higher tonic CB1 occupancy that comes from pooling 2-AG rather than AEA.

What we like here is the bench specificity. If you’re working on 2-AG-mediated retrograde signaling, CB1 synaptic plasticity, MAGL’s role in neuroinflammation, or the non-CB1 downstream targets of elevated 2-AG (GPR55, PPARs), JZL184 is probably already in your protocol. The replication record across labs is genuinely strong for a research tool compound. Papers out of Piomelli’s group, Bhatt’s group, and a long list of academic neuroscience labs have built on the Scripps scaffold without needing to re-validate the selectivity claims from scratch.

The limitations are real though. Novelty is low because the compound is mature; the research frontier using JZL184 is about what investigators do with it, not the compound itself. Translational signal is basically absent because JZL184 was never designed as a development candidate, and its irreversible mechanism creates tolerability concerns that have kept it out of clinical consideration. There is no human data and no active IND. The endocannabinoid axis it probes is extremely relevant to pain and neuroinflammation programs, but those programs are being run with next-generation reversible MAGL inhibitors like ABX-1431, not with JZL184. Honestly, that’s fine. JZL184’s job is to be the canonical probe, and it does that job very well. Score it accordingly.

Novelty

38

Mechanism promise

62

In-category differentiation

72

Evidence quality

62

Translational signal

24

Research bench value

78

Rationale JZL184 scores high on differentiation and bench value because it remains the reference-standard MAGL inhibitor after 15 years, with no serious competitor for clean irreversible 2-AG elevation in preclinical models; it scores low on novelty and translational signal because the compound itself is mature and has never entered human development, functioning purely as a tool rather than a drug candidate.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective MAGL inhibitor (research)

A covalent inhibitor of monoacylglycerol lipase (MAGL); the canonical research probe for elevating endogenous 2-AG.

Abstract

JZL184 (CAS 1101854-58-3; molecular formula C27H24F2N2O5; molecular weight 510.49) is a covalent piperidinyl-carbamate inhibitor of monoacylglycerol lipase (MAGL) developed by Cravatt and colleagues at Scripps. The compound carbamoylates the active-site serine of MAGL, producing irreversible enzyme inactivation. Selective for MAGL over FAAH (approximately 300-fold) and other serine hydrolases. Pharmacological consequence: elevation of endogenous 2-AG (the principal full-agonist endocannabinoid) without direct CB receptor agonism. Behavioral effects are more THC-like than FAAH inhibition (anxiolysis, analgesia, hypothermia, catalepsy at high dose), reflecting the higher tonic CB1 occupancy from elevated 2-AG. Used as the canonical MAGL inhibitor in academic neuroscience for studies of 2-AG signaling and CB1-mediated synaptic plasticity. No human clinical development.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-330Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Sodium Oxybate (GHB)

Our opinion on this compoundFederally scheduled

57/100

Canonical GHB receptor probe and approved narcolepsy drug with serious regulatory burden and limited novelty

Look, sodium oxybate is a genuinely weird compound to score because it lives in two regulatory worlds simultaneously. As Xyrem its Schedule III; as free-base GHB its Schedule I. That dual status isnt just an administrative footnote for a bench scientist. It shapes everything about sourcing, handling, institutional approval, and the realistic scope of an investigator’s research program. We’re not penalizing it for being controlled, but we’re not pretending that friction doesn’t exist either.

The pharmacology itself is interesting in a way that doesn’t fully show up until you dig into the receptor biology. GHB has two binding targets: a high-affinity, low-capacity GHB-specific receptor (Kd around 50 nM) and low-affinity GABA-B (Ki around 5 mM). At clinically relevant doses, GABA-B dominates the functional output, but the GHB receptor is a genuinely understudied piece of neuropharmacology. It’s not GABA-B, its not an opioid receptor, its not something well-mapped by standard psychopharmacology toolsets. If you’re trying to untangle GHB receptor-specific signaling from GABA-B contributions, sodium oxybate is essentially the only game in town. That gives it real probe value that pure mechanism scores alone dont fully capture.

The evidence base is solid by research-library standards. Xyrem went through multiple Phase 3 RCTs for narcolepsy and has a decade-plus of post-approval pharmacovigilance. The slow-wave sleep consolidation effect is one of the cleaner mechanistic demonstrations in clinical sleep pharmacology. European data on alcohol dependence is messier and more contested, but there’s a real multi-lab literature there, not just a single consortium claiming results nobody else can replicate.

What drags the score down is novelty, and honestly that’s appropriate. This is not a compound where a serious bench scientist is going to find white space easily. The narcolepsy mechanism is well-characterized. The GABA-B angle has baclofen as a cleaner alternative for most purposes. The alcohol dependence angle is still alive but crowded with competing pharmacological approaches. If your research program requires specifically interrogating GHB receptor biology, sodium oxybate is indispensable. If your program only tangentially touches it, the regulatory cost isnt worth it when better-characterized GABA-B probes are on the shelf.

We think this one sits around the 57 range: too mature and too well-understood to score higher on novelty, but too pharmacologically unique and too clinically validated to score lower. The GHB receptor remains one of the weirder and less-answered questions in CNS pharmacology. That keeps it above pure workhorse territory.

Novelty

30

Mechanism promise

52

In-category differentiation

60

Evidence quality

72

Translational signal

74

Research bench value

65

Rationale Calculated overall of 57 sits below both the Schedule III cap (75) and Schedule I cap (65), so no cap binds; the score reflects a mature approved drug with genuine bench utility as the only pharmacological handle on GHB receptor biology, but low novelty and a dual scheduling status that creates significant access friction for investigators.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GHB receptor agonist / GABA-B partial agonist

Sodium gamma-hydroxybutyrate; an endogenous neurotransmitter and prescription medication for narcolepsy and (controversially) alcoholism.

Abstract

Sodium oxybate (sodium 4-hydroxybutanoate, GHB; CAS 502-85-2; molecular formula C4H7NaO3; molecular weight 126.09) is the sodium salt of gamma-hydroxybutyrate, an endogenous short-chain fatty acid neurotransmitter and metabolite of GABA. The compound binds two distinct receptors: high-affinity GHB receptors (Kd approximately 50 nM, low capacity) and low-affinity GABA-B receptors (Ki approximately 5 mM, high capacity); pharmacologically meaningful effects at clinical doses are predominantly GABA-B-mediated. Approved indications: narcolepsy with cataplexy and excessive daytime sleepiness; clinical effect involves consolidation of slow-wave sleep. Used in some European countries (notably Italy, France) for alcohol withdrawal and dependence treatment. Schedule III when prescribed as Xyrem; Schedule I as illicit GHB. The narrow therapeutic index makes overdose easy and dangerous; recreational misuse with predatory drug-facilitated assault has been a significant public health issue. Plasma half-life is approximately 0.5 to 1 hour. Used as the canonical GHB receptor and GABA-B partial agonist in academic neuroscience.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-346Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Erythropoietin (EPO)

Our opinion on this compoundResearch workhorse

57/100

Canonical erythropoiesis reference probe with massive evidence base but near-zero discovery frontier value

Look, EPO is one of those compounds where the evidence base is genuinely enormous. FDA approved since 1989, hundreds of phase 3 trials, decades of mechanistic work from labs on every continent. But that same depth is precisely why it doesn’t score high on novelty or mechanism promise. The EPO receptor homodimer story, the JAK2/STAT5 cascade, BFU-E and CFU-E proliferation and survival biology: all of this is textbook. Thats not a criticism, its just a fact about where the frontier sits. You’re not publishing a career-defining paper by finding a new angle on canonical erythropoiesis signaling in 2026.

Where EPO earns real score is as a tool. If your research program touches erythropoiesis, the signaling hierarchy from hypoxia sensing through HIF-1alpha stabilization to renal EPO release to committed erythroid progenitor maturation, EPO is still the canonical probe. No substitute. Pharmacokinetics are thoroughly characterized (subcutaneous t1/2 roughly 19 to 24 hours, extended considerably with darbepoetin alfa or CERA), sourcing is reliable from pharmaceutical-grade biologics, and dose-response in animal models is well-calibrated across species. Bench utility for that specific research program is real and we scored it accordingly.

The tissue-protective EPO angle is the one question worth flagging for serious investigators. The hypothesis, originating largely from Brines and Cerami group work in the early 2000s, proposes that EPO has non-hematopoietic cytoprotective effects mediated via a heterodimer receptor complex (EPOR/CD131) distinct from the classical erythroid homodimer. This could mean cardioprotective, neuroprotective, or hepatoprotective activity independent of hematocrit elevation. But the clinical data here has been consistently disappointing. ENRICH and RECESS in cardiac surgery were negative. Neuroprotection work (Ehrenreich group in schizophrenia and TBI contexts) showed early signal that didn’t replicate cleanly. The mechanism is interesting. The translational arrow in that direction is weak.

We think EPO is the clearest example of a compound where evidence quality and approved-indication translational signal are both near the ceiling, but novelty and mechanism promise are low because the relevant questions have been answered. It’s a reference standard, not a frontier target. If your program needs to characterize erythroid biology or probe JAK2/STAT5 in erythroid progenitors, it belongs in the library. If you’re hunting for novel biology, there isnt much left to hunt here. The intellectually interesting metabolism work has largely migrated to HIF prolyl hydroxylase inhibitors like roxadustat and daprodustat, which achieve the same upstream effect while opening genuinely new pharmacology EPO cant access. That’s where the mechanistic questions now live.

Novelty

20

Mechanism promise

35

In-category differentiation

60

Evidence quality

90

Translational signal

85

Research bench value

75

Rationale EPO scores near-ceiling on evidence and translational signal for its approved indications, but novelty and mechanism promise are low because the JAK2/STAT5 erythroid biology is textbook and fully worked out. The one genuinely open question, the tissue-protective heterodimer receptor hypothesis, has produced inconsistent clinical results and doesn’t rescue the frontier score.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Glycoprotein hormone (erythropoiesis-stimulating)

The hormone that stimulates red blood cell production; recombinant human EPO is approved for anemia and is widely abused in endurance sports.

Abstract

Erythropoietin (EPO; CAS 11096-26-7; 165-amino-acid glycoprotein with three N-linked and one O-linked glycan chains; molecular weight approximately 30 kDa) is the principal regulatory hormone of erythropoiesis, produced by interstitial fibroblasts in the renal cortex in response to hypoxia. Recombinant human EPO (epoetin alfa, Procrit, Epogen) was approved by the FDA in 1989 as one of the first commercial recombinant proteins. Mechanism: binding to the EPO receptor (homodimer) on erythroid progenitor cells (BFU-E, CFU-E) prevents apoptosis and stimulates proliferation and differentiation, increasing red blood cell production over 1 to 2 weeks. Approved indications: anemia of chronic kidney disease, chemotherapy-induced anemia, anemia in zidovudine-treated HIV, anemia of prematurity, surgical blood conservation. The compound is among the most notorious performance-enhancing substances in endurance sport (cycling, distance running, cross-country skiing) owing to the oxygen-delivery advantage of supranormal hematocrit; the WADA prohibited list and modern biological passport monitoring address this. Plasma half-life is approximately 4 to 13 hours subcutaneous; longer-acting analogs (darbepoetin, methoxy polyethylene glycol-epoetin beta) extend dosing intervals. Used as the canonical erythropoiesis-stimulating agent in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-363Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 43 44 45 46 47 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.